Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...